Correlation of cisplatin sensitivity with differential alteration of EGFR expression in head and neck cancer cells

Anticancer Research

Volumn 20, Issue 2 A, 2000, Pages 899-902

  Chen, Zhuo ^a,b   Ke, Li Dao ^a   Yuan, Xiao Hua ^a   Adler Storthz, Karen ^a  

^a UNIVERSITY OF TEXAS DENTAL BRANCH AT HOUSTON   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Cisplatin; EGFR; Head and neck cancer; Human papillomavirus (HPV); mRNA; p53

Indexed keywords

CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; MESSENGER RNA;

ARTICLE; CANCER INHIBITION; CELL LINE; CONTROLLED STUDY; DRUG SENSITIVITY; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

CELL DIVISION; CELL SURVIVAL; CISPLATIN; GENE EXPRESSION REGULATION, NEOPLASTIC; HEAD AND NECK NEOPLASMS; HUMANS; KINETICS; PAPILLOMAVIRIDAE; RECEPTOR, EPIDERMAL GROWTH FACTOR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSCRIPTION, GENETIC; TUMOR CELLS, CULTURED;

EID: 0034093597     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Mueller H and Eppenberger U: The dual role of mutant p53 protein in chemosensitivityofhumancancers. Anticancer Res 16: 3845-3848, 1996.
2. Fan S, Smith ML, Rivet II DJ, Duha D, Zhan Q, Kohn KW, Fornace, Jr. AJ, and O'Connor PM: Disruption of p53 function sensitizes breast cancer MCF-7 cells to cisplatin and pentoxifylline. Cancer Res 55: 1649-1654, 1995.
3. Hawkins DS, Demers GW and Galloway DA: Inactivation of p53 enhances sensitivity to multiple chemotherapeutic agents. Cancer Res 56: 892-898, 1996.
4. Issing WJ, Wustrow TPU, Heppt W: Oncogenes related to head and neck cancer. Anticancer Res 13: 2541-2552, 1993.
5. Santini J, Formento J-F, Francoual M, Milano G, Schneider M, Dassonville O and Demard F: Characterization, quantification, and potential clinical value of the epidermal growth factor receptor in head and neck squamous cell carcinomas. Head & Neck 13: 132-139, 1991.
6. Dassonville O, Francoual M, Ramaioil A, Ramaioli A, Santini J, Schneider M, Demard F and Milano G: Expression of epidermal growth factor receptor and survival in upper aerodigestive tract cancer. J Clin Oncol 11: 1837-1878, 1993.
7. Ke LD, Adler-Storthz K, Clayman GL, Yung AWK and Chen Z: Differential expression of epidermal growth factor receptor in human head and neck cancers. Head & Neck 20: 320-327, 1998.
8. Chen Z, Adler-Storthz K, Shillitoe EJ: Mutations in the long control region of human papillomavirus DNA in oral cancer cells and their functional consequences. Cancer Res 57: 1614-1619, 1997.
9. Fricker SP: The application of sulforhodamine B as a colorimetric endpoint in cytoxicity assay. Toxicol In Vitro 8: 821-822, 1994.
10. Fujiwara T, Grimm EA, Mukhopadhyay T, Zhang W-W, Owen-Schaub LB and Roth JA: Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of the wild-type p53 gene. Cancer Res 754: 2287-2291, 1994.
11. Lei W, Mayotte J, Levitt M: Enhancement of chemosensitivity and proy,rammed cell death by tyrosine kinase inhibitors correlates with EGFR expression in non-small cell lung cancer cells. Anticancer Res 19: 221-228, 1999.
12. Mroczkowski B and Mosig G, Cohen S: ATP-stimulated interaction between epidermal growth factor receptor and supercoiled DNA. Nature 309: 270-273, 1984.
13. Scanlon KJ, Kashani-Sabet M, Miyachi H, Sowers LC, and Rossi J: Molecular basis of cisplatin resistance in human carcinomas: modal systems and patients. Anticancer Res 9: 1301-1312, 1989.
14. Eldredge ER, Korf GM, Christensen TA, Connolly DC, Getz M, and Maihle NJ: Activation of c-fos gene expression by kinase-def1cient epidermal growth factor receptor. Mol Cell Bioll 14: 7527-7534, 1994.